See the DrugPatentWatch profile for aristada
Alkermes manufactures Aristada, a long-acting injectable antipsychotic medication [1]. Aristada is prescribed to treat schizophrenia in adults [1][2]. The medication is available in two formulations: Aristada and Aristada Initio [1][3]. Aristada is administered as a once-monthly or every-two-month injection, while Aristada Initio is a starter injection given with Aristada to achieve therapeutic levels faster [3].
How does Aristada work?
Aristada contains aripiprazole lauroxil, which is a prodrug of aripiprazole [1][3]. Once injected, the prodrug is slowly converted in the body to aripiprazole, the active ingredient [3]. Aripiprazole is an atypical antipsychotic that is thought to work by affecting the activity of dopamine and serotonin in the brain [1].
When does the Aristada patent expire?
The patent landscape for Aristada is complex, involving multiple patents and potential challenges [4]. According to DrugPatentWatch.com, patents related to Aristada have expiration dates that extend into the future, but these dates can be subject to various legal and regulatory factors, including patent term extensions and potential litigation [4].
Who are Alkermes' competitors in the long-acting injectable antipsychotic market?
Alkermes faces competition from other pharmaceutical companies offering long-acting injectable antipsychotics. These competitors also target the treatment of schizophrenia and other psychotic disorders with their own formulations [5].
What are the potential risks and side effects of Aristada?
As with any medication, Aristada carries potential risks and side effects. Common side effects can include injection site reactions, insomnia, headache, and weight gain [1]. More serious, though less common, side effects may include movement disorders like tardive dyskinesia, metabolic changes, and an increased risk of death in elderly patients with dementia-related psychosis [1][2].
Can generic versions of Aristada be developed?
The development of generic versions of Aristada is contingent upon the expiration of relevant patents and any subsequent regulatory exclusivities [4]. Generic manufacturers will likely need to demonstrate bioequivalence to the branded product to gain FDA approval [5].
What clinical data supports Aristada's use?
Clinical trials have evaluated the efficacy and safety of Aristada in adult patients with schizophrenia [1][3]. These studies typically assess symptom reduction and the maintenance of treatment effects over time [3].
How is Aristada administered?
Aristada is administered by a healthcare professional as an intramuscular injection [1][3]. The injection is given into the gluteal muscle [1]. The frequency of administration depends on the specific Aristada formulation and the patient's treatment plan [3].
What is the difference between Aristada and Aristada Initio?
Aristada Initio is a starter injection that contains a higher initial dose of aripiprazole lauroxil than standard Aristada [3]. It is used to rapidly achieve therapeutic levels of aripiprazole, allowing for a faster transition to Aristada injections [3]. Aristada itself is available in monthly or every-two-month injection options for ongoing maintenance therapy [1].
Sources:
[1] https://www.alkermes.com/our-products/our-pipeline/aristada
[2] https://www.medicinenet.com/aristadaaristadainitiosideeffectsdosagepictures/article.htm
[3] https://www.aristada.com/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955530/